R&D service provider raises $150M; Austin developers push for new biotech hub; BioMarin, Omeros ready new trials;

 @FierceBiotech: Karolinska portfolio biotech Axelar says PhII lung cancer drug on promising track. More | Follow @FierceBiotech

@JohnCFierce: Clavis' Olav Hellebo says co. could be sold or shut down, but it's all down to liquidation value now. More | Follow @JohnCFierce

@RyanMFierce: Immunomedics won an $18M settlement from BoA, now it could use an R&D win with those cancer programs. WSJ Article | Follow @RyanMFierce

> Chevy Chase, MD-based Precision for Medicine, which aims to provide services to drug developers looking to speed up their clinical trial efforts, says it has raised $150 million in private equity. Release

> With blueprints in the works for a new medical school at the University of Texas, organizers are working on developing a new biotech hub near the campus. Story

> Armed with positive animal data for OMS72, Omeros is preparing to file a clinical trial application to study the antibody as a treatment for thrombotic microangiopathy, a disorder that occurs in the microcirculation of the body's organs, most commonly the kidney and brain. Release

> BioMarin Pharmaceutical ($BMRN) has submitted a CTA in the U.K. for BMN-190, a recombinant human tripeptidyl peptidase 1 for a form of Batten disease. The company expects to start enrolling patients in a Phase I/II trial in mid-2013. Release

> Immunomedics says it will get $18 million from a March 27 settlement against a broker-dealer involved in a prior investment. Release

Medical Device News

 @FierceMedDev: Seventh Sense revs up crucial trial for microneedle blood collector. More | Follow @FierceMedDev

 @MarkHFierce: The NYT has come out against not just a device tax repeal, but industry lobbying efforts to make their case. Story | Follow @MarkHFierce

 @DamianFierce: AbioMed is studying a next-gen Impella pump targeting FDA approval. Article |& Follow @DamianFierce

> Life Tech looks to expand cancer, DNA testing presence. Story

> Singapore crew tests Dx for new intestinal lymphoma. More

Pharma News

@FiercePharma: Lilly works up $180M addition to Indy insulin mfring + $80M in other projects. PR hints at city tax incentives: Release | Follow @FiercePharma

@EricPFierce: Recalls by Hospira encourage other players to jump into sterile injectable drug manufacturing. More | Follow @EricPFierce

> Merz swoops into Obagi deal with $385M bid, topping Valeant. More

> AZ's Pulmicort patent loss could cost $100M-plus. Story

Biotech Research News

@EmilyMFierce: Waiting for details today on Obama's $100M brain mapping project. Background here: Story | Follow @EmilyMFierce

> More evidence found for new anti-cancer agent. More

> Diabetes drug slows aging process in worms. Report

> Researchers launch consortium to study neurodegenerative diseases. Item

> Dutch researchers detect early Parkinson's pathology. Article

> New drug could combat resistant malaria strains. More

Pharma Manufacturing News

> Manufacturing issues still dog A.P. Pharma. Story

> Japan's Asada Milling gets warning letter. More

> Lilly doubles down on insulin plant, expands API capacity. Article

> Sanofi adding manufacturing capacity in China, Vietnam. Story

And Finally… Researchers at Rice University and the University of Texas MD Anderson Cancer Center in Houston and Mount Sinai Medical Center in New York say their 3-dimensional scaffolds should help the development of new cancer therapies. Release


Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.

The series A gives ex-Roche VP George Garibaldi a chance to realize the potential of assets that fell by the wayside at the Swiss pharma.